Core Insights - The technology and manufacturing, as well as healthcare sectors, are solidifying their positions as the dual core of investment activity, with significant financing cases concentrated in these areas [1] - The past two weeks have seen a surge in financing activities, particularly in embodied intelligence, new drug development, and advanced manufacturing [1][2] Financing Overview - A total of 23 financing events were disclosed in the domestic primary market from February 9 to February 23, 2026, with a total financing scale exceeding 38.09 billion RMB [2] - The healthcare sector completed 12 financing rounds amounting to approximately 24.44 billion RMB, while the technology and manufacturing sector completed 10 rounds totaling about 12.65 billion RMB [4] Sector Distribution - The financing distribution shows that the technology and manufacturing sector had 10 cases with a disclosed amount of approximately 12.65 billion RMB, while the healthcare sector had 12 cases with about 24.44 billion RMB [4] - The consumer services sector had only 1 case with a disclosed amount of 1 billion RMB [4] Regional Distribution - The financing activities were primarily concentrated in Shanghai, Guangdong, Beijing, Jiangsu, and Zhejiang, with Shanghai leading with 8 cases [5] Active Investment Institutions - Hillhouse Capital was notably active, completing 3 financing rounds primarily in the healthcare sector [6] Notable Financing Cases - Shanghai Yuesai Biotechnology completed a new round of financing of 50 million RMB on February 11, 2026, focusing on stem cell therapy [7] - Supervision completed over 100 million RMB in B+ round financing on February 10, 2026, for advanced imaging systems [8] - Ice Crystal Intelligent completed several million RMB in A+ round financing on February 10, 2026, focusing on cardiac intervention devices [9] - Huixin Biotechnology completed nearly 100 million RMB in A+ round financing on February 10, 2026, for exosome purification and cancer early detection [10] - Regend Therapeutics completed 350 million RMB in C round financing on February 11, 2026, focusing on regenerative medicine [11] - Beijing Zhiren Medical Technology completed 300 million RMB in A+ round financing on February 11, 2026, for brain-machine interface technology [12] - KSKD completed nearly 500 million RMB in a new round of financing on February 10, 2026, focusing on original drug development [13] - AGILINK completed several hundred million RMB in A round financing on February 11, 2026, focusing on robotic end-effectors [14] - Juwei Technology completed over 100 million RMB in A+ round financing on February 11, 2026, focusing on embodied intelligence technology [15] - Baier New Materials completed 65 million RMB in B round financing on February 11, 2026, focusing on 3D printing electronic materials [16] - INFLYNC completed over 100 million RMB in A round financing on February 11, 2026, focusing on eVTOL aircraft [18] - Xinghai Map completed 1 billion RMB in B round financing on February 11, 2026, focusing on embodied intelligence services [19] - Krey Technology completed over 100 million RMB in B round financing on February 11, 2026, focusing on micro-motor production [20] - Qunche Intelligent completed several million RMB in angel round financing on February 10, 2026, focusing on embodied intelligence technology [21]

一句话趋势：科技与制造、医疗健康双核心格局进一步巩固，两大领域包揽本周绝大多数融资案例。亿元级及以上大额融资密集落地，具身智能、新药研 发、高端制造等细分赛道成为资本布局重点，头部投资机构持续加码硬科技与医疗创新领域。 过去两周，科技与制造领域以多笔亿元级大额交易持续领跑市场，稳居融资核心地位：具身智能技术研发与应用的高科技企业具微科技获得超亿元A+轮融 资；微电机制造企业克瑞科技完成过亿元B轮融资。 此外，北微传感、ELITEAL、青昀新材等细分赛道企业均获投资机构加码，项目覆盖具身智能、高端制造等多个硬科技领域，资本与产业链对技术研发与 产业化落地的关注度持续提升，同时核心技术自主可控成为企业融资后重点布局方向。 医疗健康领域迎来融资热潮，大额交易密集落地，AI赋能医疗、创新生物疗法成为布局重点：创新型医疗器械公司北京智冉医疗科技有限公司完成3亿人民 币新一轮融资；面向结构性心脏病、电生理市场的冰晶智能获数千万元A+轮融资。 21创投不完全统计，2026年2月9日—2月23日，国内一级市场共披露融资事件23起，覆盖科技与制造、医疗健康、消费服务三大领域。其中有16笔融资披露 了融资金额和币种信息，披露融资 ...